TPG-backed Bicara Therapeutics shares jump 45.8% in stellar market debut
Sept 13 (Reuters) - Shares of Bicara Therapeutics BCAX.O rose 45.8% in their market debut on Friday, signaling strong investor interest for the TPG-backed cancer therapy developer. (Reporting by Vedant Vinayak Vichare and Arasu Kannagi Basil in Bengaluru; Editing by Leroy Leo) ((vedant.vinayakvichare@thomsonreuters.com))
Recent news on Bicara Therapeutics
See all newsBrief: Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Bicara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027
Brief: Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors